Table 1.

Demographics and clinical characteristics of CMML patients with or without chromosomal abnormalities

	Total N (%)	Normal karyotype	Abnormal karyotype	P*
Number of Patients	417	292 (70%)	125 (30%)
Age (years)
Median (range)	69 (27–92)	69 (30–92)	69 (27–87)	0.1771
<70 (No. of patients)	211	146	65	0.7486
≥ 70 (No. of patients)	206	146	60
Gender				0.998
Male	292	204	88
Female	125	88	37
WHO classification				0.1678
CMML-1	331	237	94
CMML-2	86	55	31
WBC counts (x109/L)
Median (range)	16 (2.6–209)	17.4 (2.6 – 209)	15.4 (3.3 – 116)	0.1956
<13 (No. of patients)	187	117	70	0.455
≥ 13 (No. of patients)	230	175	55
Hemoglobin (g/dL)
Median (range)	10.7 (3.8–16.7)	10.9 (5.9–16.7)	10.2 (3.8 – 15.8)	0.0013
≥ 10 (No. of patients)	265	192	73	0.1529
<10 (No. of patients)	152	100	52
Platelet (x109/L)
Median (range)	102 (5–820)	108 (5 – 809)	90 (6 – 820)	0.0089
≥ 100 (No. of patients)	217	162	55	0.0316
<100 (No. of patients)	200	130	70
PB blasts (%)
Median (range)	0 (0–15)	0 (0–15)	0 (0–13)	0.0746
< 5 (No. of patients)	391	278	113	0.0630
≥ 5 (No. of patients)	26	14	12
PB Immature Myeloid Cells
Presence	226	149	77	0.0536
Absence	191	143	48
PB Monocyte (x109/L)
Median (range)	3.3 (1.03–71.9)	3.23 (1.03–64.4)	3.36 (1.03–71.9)	0.7783
≥ 3 (No. of patients)	217	145	72	0.1642
<3 (No. of patients)	200	147	53
BM cellularity (%)
Median (range)	90 (30–100)	90 (30–100)	80 (30–100)	0.0876
BM blasts (%)
Median (range)	4 (0–9)	4 (0–19)	5 (0–18)	0.5103
< 10 (No. of patients)	333	233	100	0.9618
≥ 10 (No. of patients)	84	59	25
Survival (months)
Overall Survival (median)	27	33	19	<0.0001
AML transformation
Accumulated (%)	25.9	23.6	31.2	0.1109
2-year (%)	18.2	13.7	28.8	0.0005

^*Comparisons between patients with or without cytogenetic abnormalities.

AML: Acute myeloid leukemia; BM: bone marrow; CMML: chronic myelomonocytic leukemia; PB: peripheral blood; WBC: white blood cell count.